This review summaries a recent presentation given by Professor Gordon Cook, Dr Georgia McCaughan, and Dr Wojt Janowski which highlighted key findings from the phase 3 MAIA trial and their implications for the management of frail, elderly, and high-risk newly diagnosed Multiple Myeloma populations.
Please login below to download this issue (PDF)